This is in line with previously published data showing increased sensitivity of cancer cells with high MYC/MYCN-expression to PARPi including glioblastoma stem-like cells, neuroblastoma, multiple myeloma and medulloblastoma cells in vivo and in vitro [44–47]. The gene discussed is MYCN; the disease is medulloblastoma.